RE:U.S. funding 1.6B$ for Novavax's COVID-19 Novavax is exclusively a vaccine company.
It currently has a 4.2B$ market valuation for 222M$ in revenues (Dec. 2021). An oncology biotech with an approved drug is worth much more than a vaccine, just based on the fact that a late-stage cancer is usually more life-threatening than a virus.
Novavax's current share price is 54$US.
In Jan. 2020, it was 6$US. July 2020, it touched 170$US. Its high was in Feb. 2021, 289$US. Now 54$US.
222M$ in revenues (Dec. 2021).
Our turn will come. 0.32$CAN (0.23$US) is simply an amazing opportunity. We just need to confirm our clear superiority over competition via a Breakthrough designation with our Ph. 2b data.